Study of Oglemilast for the Prevention of Asthma.

Efficacy and Safety of Oglemilast in the Prevention of Exercise-Induced Bronchospasm

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00322283

Enrollment

Registered

2006-05-05

Start date

2006-05-31

Completion date

2006-10-31

Last updated

2012-04-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Exercise-Induced Asthma

Keywords

oglemilast, asthma, exercise, prevention, prophylaxis

Brief summary

The purpose of this study is to determine whether it is effective in the treatment of exercise-induced asthma and investigate the safety of oglemilast.

Interventions

DRUGOglemilast

Oglemilast, 15mg once per day, oral administration

DRUGPlacebo

Dose-marched placebo, once per day, oral administration

Study design

Allocation

NON_RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

PREVENTION

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 50 Years

Healthy volunteers

Inclusion criteria

* stable mild asthma patients who exhibit at least a 20% decrease in FEV1 following exercise.

Exclusion criteria

* pulmonary disease other than asthma, psychiatric illness, active cardiac disease, high blood pressure, history of substance abuse, current smokers.

Design outcomes

Primary

Measure	Time frame
To determine the efficacy of oglemilast as compared to placebo in preventing exercise-induced asthma following 15 days of treatment.	—

Secondary

Measure	Time frame
To evaluate the safety of oglemilast over 2 weeks as determined by adverse events, physical examinations, vital signs, electrocardiograms, and laboratory examinations.	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026